Clareo Health | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
No active brain metastases
Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
You may not be if
Mixed small-cell lung cancer and NSCLC histology
Myocardial Infarction within 6 months of study Day 1
Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) or known CYP3A4 sensitive substrates or P-gp substrates
Therapeutic or palliative radiation therapy within 2 weeks of study day 1
Unable to take oral medication
Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans
